In estrogen receptor α (ERα)-positive breast cancers, the ability of AhR to promote the degradation of ERα in a ligand-dependent manner drives antiproliferative effects, and this antiestrogenic activity represents one mechanism of tumor suppression [144]. The gene discussed is ESR1; the disease is breast carcinoma.